NCT06688058View on ClinicalTrials.gov

A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Healthy
Interventions
BIOLOGICAL

V540D

Experimental vaccine and adjuvant administered via intramuscular (IM) injection

BIOLOGICAL

GARDASIL®9

Suspension administered via IM injection

Trial Locations (4)

31406

ACTIVE_NOT_RECRUITING

Velocity Clinical Research, Savannah ( Site 0005), Savannah

33024

ACTIVE_NOT_RECRUITING

Research Centers of America ( Hollywood ) ( Site 0001), Hollywood

37920

ACTIVE_NOT_RECRUITING

Alliance for Multispecialty Research, LLC ( Site 0004), Knoxville

64114

RECRUITING

Alliance for Multispecialty Research, LLC ( Site 0003), Kansas City

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY